EPHB6

Across TCGA pan-cancer cohorts, EPHB6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EPHB6 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EPHB6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPHB6 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where EPHB6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.352	1.000	.004	29	view →
PDAC	DFS	Quartile	II,III,IV	0.454	0.771	.019	15	view →
LUAD	DFS	Median	All	0.417	1.000	.012	4	view →
HNSC	OS	Quartile	IV	0.485	0.776	.017	2	view →
GBM	DFS	Tertile	All	0.234	0.468	.028	2	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.382	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EPHB6–CCRCC (DFS)

Open the CCRCC breakdown →